OGT-719 

OGT-719 is a potent, orally active nucleoside analogue that targets the asialoglycoprotein receptor (ASGP-R). OGT-719 inhibits growth of metastatic colorectal tumors in the liver of nude mice. OGT-719 can be used for primary hepatocellular carcinoma and colorectal liver metastases research^[1].

OGT-719 (80 mM, 4 h) inhibits thymidylate synthase (TS) activity in C170HM2 cells at a concentration of 80 mM (approximately 2xIC₅₀)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

OGT-719 (1500 mg/kg/day, p.o., b.i.d. for 32 days) significantly inhibits growth of metastatic colorectal tumors in the liver of nude mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

292.22

C₁₀H₁₃FN₂O₇

185843-61-2

O=C1NC(C(F)=CN1[C@H]2[C@@H]([C@H]([C@H]([C@@H](CO)O2)O)O)O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Rohlff C, et al. A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2. Cancer Res. 1999 Mar 15;59(6):1268-72.  [Content Brief]